Shanghai – October 21, 2026 -- WuXi Biologics (2269.HK) won the Jade Award, the highest distinction at The Asset Corporate Sustainability Leadership Awards 2026, and was the only pharmaceutical company among this year's Jade recipients. The contract research, development and manufacturing organization (CRDMO) also took the Best in Transition (Hong Kong) award.
Jade Award rewards ESG integration into strategy and operations
The program confers the Jade Award on organizations that integrate sustainability into strategy and operations. Judging criteria include governance, resilience, innovation, transformation and long-term value creation. WuXi Biologics says the award reflects investor and industry recognition of its ESG governance and its use of sustainability to strengthen long-term competitiveness.
CEO Dr. Chris Chen, who also chairs the company's ESG Committee, said WuXi Biologics will keep strengthening ESG governance and advancing its Green CRDMO solutions to support the pharmaceutical industry's green transition.
Four-tier governance structure runs from strategy to execution
The ESG Committee leads a four-tier governance framework covering strategy formulation, resource allocation, professional implementation and business execution. WuXi Biologics says the framework embeds sustainability in strategic decisions and day-to-day operations.
The company cites the following external ESG ratings and index inclusions:
- MSCI AAA rating
- EcoVadis Platinum Medal
- Morningstar Sustainalytics' highest "Negligible Risk" rating, plus recognition as an Industry and Regional ESG Leader
- Inclusion in the Dow Jones Best-in-Class World Index and Emerging Markets Index
Green CRDMO and Smart ESG platform drive the Best in Transition award
The Best in Transition award recognizes progress in green and digital transformation. Under its end-to-end Green CRDMO offering, WuXi Biologics applies green principles across the biologics research, development and manufacturing lifecycle. It works on resource efficiency and environmental performance through green technology innovation, energy efficiency, renewable energy adoption and value-chain collaboration.
The company also runs a digital Smart ESG management platform. The platform strengthens data integration, dynamic monitoring and analysis, which WuXi Biologics says improves the efficiency of ESG information management and the quality of decisions.